EurekAlert! -
25 May 2020 06:00
(Osaka University) Researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University identified the amino acid arginine as a potential disease-modifying drug for polyglutamine diseases, including familial spinocerebellar ataxia and Huntington disease. Using various mice models of polyglutamine diseases, they showed that arginine prevents polyglutamine protein aggregation, improves motor function and suppresses neurodegeneration of mice. The results of this st...
Share this Article
Comment on this Article
Please to comment